French Biotech SeaBeLife Secures €2M for Dry AMD, Hepatitis Treatments
SeaBeLife, a French biotech company based in Roscoff, has secured €2 million in a pre-Series A funding round. The company is developing innovative treatments for dry age-related macular degeneration (AMD) and severe acute hepatitis, two areas with significant unmet need.
SeaBeLife's pipeline includes lead candidates SBL03 for dry AMD and SBL01 for severe acute hepatitis. Both target regulated cell death pathways, necroptosis and ferroptosis, offering a dual-target approach not currently available on the market.
The company, led by a scientific founding team with expertise in cellular biology, toxicology, and pharmacology, aims to transform organ protection. Clinical trials for these promising candidates are expected to begin in 2026.
SeaBeLife has raised a total of €9 million through equity and public funding. The latest €2 million will support two core therapeutic programmes, funding clinical studies and scaling up development of the pipeline. The company is preparing for a larger Series A round to further advance its innovative drug development.
SeaBeLife's successful fundraising will enable it to progress its first-in-class small molecules targeting dry AMD and severe acute hepatitis into clinical trials. The company's unique approach to organ protection has the potential to revolutionize treatment in these areas.
